-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Latte cats continue to "please out" a number of breeds with the 2020 edition of the National Health Insurance Directory.
compared to the 150 varieties transferred in 2019, the principle of this transfer is still low clinical value, the abuse of obvious, better alternative drugs, as well as domestic market but no effective approval of drugs, such as saquinave.
2020 health insurance out of the drug catalog source: 2019, 2020 health insurance catalog, The Emmy industry research finishing no bright spots, strong alternative drugs, three not missing a 2020 health insurance catalog of strong heart glycosides Cardiac therapy drugs, called out alfalfa glycoside propylene, retained glycosin, deacetyl hair anthroposide and toxic hair flower glycoside K, 4 drugs clinically mainly used for acute and chronic heart failure, atrial fibrillation and arrhythroposis on the room of sexual titration.
of these, both hairy glycoside propylene and geocosin belong to the artery yellow strong heart medicine.
is used intravenously, mainly for emergency patients, and tricotsin is mainly taken orally, mainly for patients with long-term use of strong heart drugs.
gap between the therapeutic effect and the amount of poisoning is greater than that of deacetyl anthroposide, and in the solution is not as stable as deacetyl anthroposide, so clinical drug use more of the latter.
and toxic edoxycoside K are suitable for patients with articide yellow ineffectiveness, but also for patients with acute heart failure with normal heart rate or slow heart rate atrial fibrillation.
In the Ameda sample public hospital database, the sales amount of the generic name Gaoxin in 2019 and the first three quarters of 2020 was about 23.86 million yuan and 18.88 million yuan;
drugs can be replaced in terms of efficacy, and there is no more prominent use value than their peers, which means it is only a matter of time before the catalog is eddested.
In addition, the medical insurance directory called kabimazole is a pre-drug of methazole, metabolism in the body into methylmythyl, methylmythyl by blocking the production of thyroid hormone and play an anti-hyperthyroid function.
February 2019, the UK Medicines and Health Products Authority (MHRA) issued two messages warning of the risks associated with the use of carbidium.
information indicates that the use of kabimazole may lead to a risk of congenital malformations and warns patients of childbearing age to strictly contraception, and that treatment of the drug should be stopped immediately and permanently if acute pancreatitis occurs during treatment with kabimazole.
Furthermore, the EU review of epidemiological studies and case reports concluded that there was evidence of an increased risk of kabimazone and congenital malformations, particularly during pregnancy between 1 and 3 months and at high doses (15 mg and above daily).
is more clinically suitable for patients who need slow release.
in the Ameda sample public hospital database, there was no sales performance of Carbie Marzo.
, highly replaceable, poor sales performance, and potential security risks may be important factors in Kabimazazine being eddested from the catalog.
for businesses, whether their varieties can stay in the health insurance catalog depends most on clinical value.
is their own product single drug efficacy is good enough to fight the same kind of invincible hand? Or an irreplaceable, exclusive variety? Or hasn't the hammer hit him on the head yet? This requires enterprises to do a full consideration, the advantages of products left in health insurance is what, and Mo and so on when kicked out of the health care bureau only to return to God, forced to jump off the cliff.
, on the other hand, the "normalization" of innovative drugs and their inclusion in health insurance is an unprecedented impact on older drugs, but that doesn't mean they're left with only one way to "get out."
If the efficacy of a single drug is not as good as that of new drugs, then the old drugs can also give full play to the advantages of the scale of use, the use of clinical data accumulated in the market over the years, the use of the situation, to find a "solution to clinical needs" breakthrough point.
can you produce better results in combined drug use? Is there an opportunity to develop new adaptations? Can different dosage forms and different medication strategies improve patient prognostics? The arrival of new drugs means that old ones have to "race" with new ones.
Of course, the research and development of new drugs, market also need time, if enterprises take advantage of many years to occupy the clinical advantages of the market, confirm the clinical value of varieties, compared with similar and even new drugs have outstanding advantages, can bring certain pharmaceutical economic benefits to society and so on, which means that there are more "voice" in the market, "right to exist."
。